Molecular Partners (MOLN) Stock Price, News & Analysis

Company Overview

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland, and listed on Nasdaq under the symbol MOLN. The company develops targeted therapies using its proprietary DARPin platform, which is designed to create small, modular proteins that can bind selectively to disease-related targets and be engineered into multi-specific medicines.

Molecular Partners’ research and development activities have focused primarily on oncology and immuno-oncology, including treatments intended to engage or modulate the immune system and address complex biological targets. The company has also developed antiviral candidates, including ensovibep, a DARPin-based therapy investigated for the treatment of COVID-19. Its pipeline has included internally developed programs as well as candidates advanced through collaborations with pharmaceutical and biotechnology companies.

Founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETH Zurich), Molecular Partners serves global pharmaceutical and biotechnology markets through research, clinical development and strategic partnerships. The company’s programs remain subject to clinical testing and regulatory review, and its focus may evolve as development priorities change.

Key Stats

• Today's Range: $3.92 to $3.92
• 50-Day Range: $3.77 to $4.61
• 52-Week Range: $3.53 to $5.36
• Volume: 757 shs
• Average Volume: 4,493 shs
• Market Capitalization: $163.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.38
• Consensus Rating: Hold

Molecular Partners Stock Analysis - MarketRank™

Molecular Partners scored higher than 39% of companies evaluated by MarketBeat, and ranked 459th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Molecular Partners has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Molecular Partners has a consensus price target of $8.38, representing about 107.0% upside from its current price of $4.05.

Amount of Analyst Coverage

Molecular Partners has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Molecular Partners are expected to grow in the coming year, from ($1.28) to ($0.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Molecular Partners is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Molecular Partners is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Molecular Partners has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Molecular Partners has been sold short.

Short Interest Ratio / Days to Cover

Molecular Partners has a short interest ratio ("days to cover") of 0.21, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Molecular Partners has recently decreased by 0.46%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Molecular Partners does not currently pay a dividend.

Dividend Growth

Molecular Partners does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Molecular Partners this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Molecular Partners insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.93% of the stock of Molecular Partners is held by insiders.

Percentage Held by Institutions

26.55% of the stock of Molecular Partners is held by institutions.

Company Calendar

• Last Earnings: 8/25/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MOLN
• CIK: 1745114
• Web: www.molecularpartners.com
• Phone: 41-44-755-7700
• Fax: N/A
• Employees: 134
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Molecular Partners: $8.38
• High Price Target: $13.00
• Low Price Target: $3.75
• Potential Upside/Downside: +107.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -68.36%
• Return on Assets: -54.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.27
• Quick Ratio: 7.27

Sales & Book Value

• Annual Sales: $5.65 million
• Price / Sales: 28.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.40 per share
• Price / Book: 1.69

Miscellaneous

• Outstanding Shares: 40,380,000
• Free Float: 37,981,000
• Market Cap: $163.34 million
• Optionable: Not Optionable
• Beta: 1.11